A multi-center, double-blind, randomized, Phase II trial evaluation of the effectiveness of PR013 topical ophthalmic drops in patients aged 10 years and older with allergic conjunctivitis

Trial Profile

A multi-center, double-blind, randomized, Phase II trial evaluation of the effectiveness of PR013 topical ophthalmic drops in patients aged 10 years and older with allergic conjunctivitis

Planning
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Hypochlorous acid (Primary)
  • Indications Allergic conjunctivitis
  • Focus Therapeutic Use
  • Sponsors Realm Therapeutics
  • Most Recent Events

    • 04 Aug 2017 New trial record
    • 02 Aug 2017 According to a Realm Therapeutics media release, the company will review efficacy data in the first half of 2018.
    • 02 Aug 2017 According to a Realm Therapeutics media release, the company has submitted IND application to the U.S. FDA to initiate this trial later in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top